Khiron Life Sciences Corp.

Good morning, and welcome to the Keyron Life Sciences Report's third quarter fiscal year 2021 financial results conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad. To withdraw your question, please press star then two. Please note this event is being recorded I'd like to turn the conference over to Robert Bloom. Please go ahead.

All right. Thank you very much, Anthony. Good morning, everyone, and thank you for joining us today. I'm Robert Bloom, and with me on the call today are Alvaro Torres, Chief Executive Officer, Swapen Kakamanu, Chief Financial Officer, and Franziska Kaderbach, Europe President. Before we begin, please note the following caution respecting forward-looking statements, which is made on behalf of Chiron Life Sciences, and all of its representatives on this call. The statements made on this call will contain forward-looking information that involves risks and uncertainties, including those introduced by the COVID-19 pandemic. Actual results could differ materially from a conclusion, forecast, or projection in the forward-looking statement information. Certain material factors or assumptions were applied in drawing a conclusion or making a forecast or projection as reflected in the forward-looking information. Additional information about the material factors that could cause actual results to differ materially from the conclusions, forecasts, or projections in the forward-looking information and the material factors or assumptions that were applied in drawing a conclusion or making a forecast or projection as reflected in the forward-looking information are contained in Chiron Life Sciences filings with the Canadian and provincial securities regulators, which are available on the CDAR website at SEDAR.com. To provide a brief agenda, we'll start with a discussion of the quarter where Alvaro will walk through some of the key highlights before he turns it over to Swapen to run through the Chiron financial results. After that, we'll dive into key catalysts in each market that will drive growth, and we'll wrap up with a Q&A session. Now with that, it's my pleasure to turn the call over to Alvaro Torres, CEO and Director. Please proceed.

Thank you, Robert, and thank you, everybody, for joining us today. Today we'll be discussing our financial results for the third quarter. These results continue to show how unique and strong our patient-focused strategy is. We are breaking significant revenue and gross profit milestones. This has been five straight quarters of continuous medical cannabis revenues with more than 85% gross profits in Latin America and Europe. At the same time, we are continuing to show a very strong global medical services business that will continue to attract and retain patients, and I think we are just in the first stages of our potential, and of course, I'm very proud of the team who has helped been accomplishing these milestones under very different difficult circumstances worldwide. I mean, I think what we've been able to achieve so far is placing Chiron at the top of this new nascent medical industry in Latin America and Europe. I hope that today you'll be able to see the catalysts that are going to take us to the next stages, next quarter and beyond. So with that introduction, I'm going to ask Suapan, our CFO, to provide more details on the financials, And then myself and Francie, the president of Europe, will return to talk to you about the operational highlights and what we're looking at the next category that are going to continue to fuel this tremendous growth that we're able to show this quarter. Thank you. Swapn, please.